We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
TECH Stock Might Rise Following the Leo Shipping Announcement
Read MoreHide Full Article
Bio-Techne Corporation (TECH - Free Report) recently began shipping the Leo System, powered by Simple Western Technology. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
Leo will enable Bio-Techne’s customers to accelerate their cutting-edge science and bring next-generation therapies to market faster.
TECH Stock Likely to Gain From the Development
Since the announcement on March 10, Bio-Techne’s shares dipped 2.3%, closing at $62.90 on Monday.
Following its early access launch, the company is experiencing significant customer interest in the next-generation high-throughput simple Western platform, Leo. Accordingly, we expect the recent shipment of Leo to boost the market sentiment toward TECH stock in the upcoming days.
Bio-Techne has a market capitalization of $9.24 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.5% revenue improvement. It delivered a trailing four-quarter average earnings surprise of 1.55%.
About Bio-Techne’s Leo
Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run. It provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies.
Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Additionally, it features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.
Early adopters are thrilled with Leo’s power. Meanwhile, beta testers praised its robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays.
Industry Prospects Favor Bio-Techne
Per a Grand View Research report, the global western blotting market size was valued at $1.97 billion in 2024 and is projected to witness a compound annual rate (CAGR) of 6.01% from 2025 to 2030. The rising rate of brain disorders and increasing research initiatives in the biotech and pharma sectors are driving market growth.
Image Source: Zacks Investment Research
Other Recent Developments by Bio-Techne
Earlier this month, Bio-Techne’s brand, Asuragen, inked a partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only AmplideX Nanopore Carrier Plus Kit is a new genetic panel that will support software analysis for carrier screening research.
Last month, the company launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with advanced sensitivity and specificity, the Advanced Cell Diagnostics branded RNAscope probe portfolio now covers more than 70,000 unique probes across more than 450 species.
TECH Stock Price Performance
In the past year, TECH’s shares have lost 19.3% compared with the industry’s decline of 9.9%.
TECH’s Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each.
Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
TECH Stock Might Rise Following the Leo Shipping Announcement
Bio-Techne Corporation (TECH - Free Report) recently began shipping the Leo System, powered by Simple Western Technology. Leo offers the throughput and precision of standard ELISAs in a fully automated western blot assay, expanding applications in bioanalytical workflows from discovery through commercialization.
Leo will enable Bio-Techne’s customers to accelerate their cutting-edge science and bring next-generation therapies to market faster.
TECH Stock Likely to Gain From the Development
Since the announcement on March 10, Bio-Techne’s shares dipped 2.3%, closing at $62.90 on Monday.
Following its early access launch, the company is experiencing significant customer interest in the next-generation high-throughput simple Western platform, Leo. Accordingly, we expect the recent shipment of Leo to boost the market sentiment toward TECH stock in the upcoming days.
Bio-Techne has a market capitalization of $9.24 billion. The Zacks Consensus Estimate for the company’s fiscal 2025 earnings indicates a 5.1% year-over-year increase on a 5.5% revenue improvement. It delivered a trailing four-quarter average earnings surprise of 1.55%.
About Bio-Techne’s Leo
Leo enables the simultaneous processing of up to 100 samples in a single 3-hour run. It provides the experimental size, precision and reproducibility necessary for robust analytical grade protein quantitation for use in submissions to regulatory agencies.
Leo expands upon existing Simple Western platforms that offer automated protein size resolution and antibody-based protein detection by dramatically improving sample throughput and enhancing the reproducibility of protein quantitation. Additionally, it features enhanced Compass for Simple Western Software, with advanced analysis capabilities and improvements to better support 21 CFR Part 11 Compliance.
Early adopters are thrilled with Leo’s power. Meanwhile, beta testers praised its robust performance, data quality, and wide range of applications, including targeted protein degradation, clinical biomarker studies, gene therapy potency assays, quality control and release assays.
Industry Prospects Favor Bio-Techne
Per a Grand View Research report, the global western blotting market size was valued at $1.97 billion in 2024 and is projected to witness a compound annual rate (CAGR) of 6.01% from 2025 to 2030. The rising rate of brain disorders and increasing research initiatives in the biotech and pharma sectors are driving market growth.
Image Source: Zacks Investment Research
Other Recent Developments by Bio-Techne
Earlier this month, Bio-Techne’s brand, Asuragen, inked a partnership with Oxford Nanopore Technologies to launch the AmplideX Nanopore Carrier Plus Kit. The research-use-only AmplideX Nanopore Carrier Plus Kit is a new genetic panel that will support software analysis for carrier screening research.
Last month, the company launched an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology research and the development of next-generation therapeutics and diagnostics. Designed to deliver spatial precision with advanced sensitivity and specificity, the Advanced Cell Diagnostics branded RNAscope probe portfolio now covers more than 70,000 unique probes across more than 450 species.
TECH Stock Price Performance
In the past year, TECH’s shares have lost 19.3% compared with the industry’s decline of 9.9%.
TECH’s Zacks Rank and Key Picks
Bio-Techne currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical space are Masimo (MASI - Free Report) , Boston Scientific (BSX - Free Report) and Cardinal Health (CAH - Free Report) . At present, Masimo sports a Zacks Rank #1 (Strong Buy), whereas Boston Scientific and Cardinal Health carry a Zacks Rank #2 (Buy) each.
Masimo’s shares have rallied 30.1% in the past year. You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for MASI’s 2024 earnings per share (EPS) have increased 1.2% to $4.10 in the past 30 days. MASI’s earnings beat estimates in each of the trailing four quarters, the average surprise being 17.1%. In the last reported quarter, it posted an earnings surprise of 16.6%.
Estimates for Boston Scientific’s 2025 EPS have jumped 2.9% to $2.85 in the past 30 days. Shares of the company have surged 56.7% in the past year compared with the industry’s growth of 12.5%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 8.25%. In the last reported quarter, it delivered an earnings surprise of 7.69%.
Estimates for Cardinal Health’s fiscal 2025 EPS have increased 1.5% to $7.94 in the past 30 days. Shares of the company have jumped 15.2% in the past year against the industry’s 4.1% decline. CAH’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 9.6%. In the last reported quarter, it delivered an earnings surprise of 10.3%.